Pfizer pregabalin

NDA filing plans for Neurontin (gabapentin) successor will proceed despite FDA clinical hold decision related to tumor findings in mice. Pfizer has stopped enrolling patients in studies of pregabalin for chronic pain while it discusses the findings. Pfizer notes that rat studies and other toxicology tests show no signs of increased tumor rates